CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · IEX Real-Time Price · USD
2.100
-0.140 (-6.25%)
Jul 19, 2024, 4:00 PM EDT - Market closed
CytoMed Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for GDTC stock has a target of 5.00, which predicts an increase of 138.08% from the current stock price of 2.10.
Analyst Consensus: Buy
* Price targets were last updated on Jun 11, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for GDTC is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Apr '24 | May '24 | Jun '24 | Jul '24 |
---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 |
Buy | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Benchmark | Benchmark | Buy Reiterates $5 | Buy | Reiterates | $5 | +138.08% | Jun 11, 2024 |
Benchmark | Benchmark | Buy Reiterates $5 | Buy | Reiterates | $5 | +138.08% | Dec 4, 2023 |
Benchmark | Benchmark | Buy Initiates $5 | Buy | Initiates | $5 | +138.08% | Jul 21, 2023 |
Financial Forecast
Revenue This Year
530.40K
Revenue Next Year
530.40K
from 530.40K
EPS This Year
-0.17
from -0.39
EPS Next Year
-0.20
from -0.17
Revenue Forecast
Revenue | 2024 | 2025 |
---|---|---|
High | 546,000 | 546,000 |
Avg | 530,400 | 530,400 |
Low | 509,600 | 509,600 |
Revenue Growth
Revenue Growth | 2024 | 2025 |
---|---|---|
High | - | 2.9% |
Avg | - | - |
Low | - | -3.9% |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | -0.18 | -0.21 |
Avg | -0.17 | -0.20 |
Low | -0.17 | -0.20 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.